GLP1R and steatosis: Recently, we and others [39,40,41] have shown that the GLP-1R agonist Exendin-4 (Ex-4) reduces the fat content in an in vitro cell model of steatosis by inhibiting hepatic lipogenesis through activation of β-catenin signaling and modulation of the expression of several lipogenesis genes.